# Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

> **NCT06307093** · PHASE1 · UNKNOWN · sponsor: **R-Pharm** · enrollment: 90 (actual)

## Conditions studied

- Skin Melanoma
- Squamous Non-small-cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** RPH-075
- **DRUG:** Keytruda®

## Key facts

- **NCT ID:** NCT06307093
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2023-12-11
- **Final completion:** 2025-07
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06307093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06307093, "Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06307093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*